Vernalis PLC | Income Statement

Fiscal year is July-June. All values GBP Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
14,084.00
11,874.00
13,254.70
12,034.00
20,790.00
Cost of Goods Sold (COGS) incl. D&A
2,670.00
1,366.00
1,557.30
2,598.00
3,101.00
Gross Income
11,414.00
10,508.00
11,697.40
9,436.00
17,689.00
SG&A Expense
18,933.00
19,033.00
20,296.80
35,513.00
44,300.00
EBIT
7,519.00
8,525.00
8,599.40
25,681.00
26,102.00
Unusual Expense
1,608.00
-
57.00
2,651.00
-
Non Operating Income/Expense
783.00
286.00
2,256.30
7,440.00
1,748.00
Pretax Income
6,274.00
5,237.00
6,172.70
15,299.00
23,746.00
Income Tax
2,273.00
2,297.00
1,905.30
804.00
2,184.00
Consolidated Net Income
4,001.00
2,940.00
4,267.40
14,495.00
21,562.00
Net Income
4,001.00
2,940.00
4,267.40
14,495.00
21,562.00
Net Income After Extraordinaries
4,001.00
2,940.00
4,267.40
14,495.00
21,562.00
Net Income Available to Common
4,001.00
2,940.00
4,267.40
14,495.00
21,562.00
EPS (Basic)
0.01
0.01
0.01
0.03
0.04
Basic Shares Outstanding
442,115.00
442,225.00
442,280.00
455,258.00
526,328.00
EPS (Diluted)
0.01
0.01
0.01
0.03
0.04
Diluted Shares Outstanding
442,115.00
442,225.00
442,280.00
455,258.00
526,328.00
EBITDA
5,744.00
7,159.00
7,582.70
24,361.00
24,565.00
Other Operating Expense
-
-
-
396.00
509.00
Non-Operating Interest Income
420.00
3,002.00
227.30
291.00
608.00

About Vernalis

View Profile
Address
100 Berkshire Place
Winnersh Berkshire RG41 5RD
United Kingdom
Employees -
Website http://vernalis.com
Updated 09/14/2018
Vernalis Plc is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U. S.